Neonatal alloimmune thrombocytopenia with significant HLA antibodies

Grainger, John D.; Morrell, G.; Yates, Julie; DeLeacy, D.

doi:10.1136/fn.86.3.f200

Cited by 14 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In humans, MHC class I alloantibodies in individual cases of fetal/neonatal alloimmune thrombocytopenia (FNAIT) have been reported a number of times during the past decades (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25). In addition to thrombocytopenia, the presence of an associated neutropenia is noticed in a few cases (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28).…”

Section: Discussionmentioning

confidence: 99%

Alloantibodies against MHC Class I: A Novel Mechanism of Neonatal Pancytopenia Linked to Vaccination

Foucras

Corbière

Tasca

et al. 2011

The Journal of Immunology

View full text Add to dashboard Cite

Fetal/neonatal alloimmune thrombocytopenia is a frequent disease in humans where alloantibodies against platelet Ags lead to platelet destruction and hemorrhage. Although a role in the disease for Abs against MHC has been suspected, this has not been formally demonstrated. Since 2007, a hemorrhagic syndrome due to thrombocytopenia and designated as bovine neonatal pancytopenia (BNP) has been recognized in calves in several European countries. An inactivated antiviral vaccine is strongly suspected to be involved in this syndrome because of its highly frequent use in the dams of affected calves. In this study, we show that BNP is an alloimmune disease, as we reproduced the signs by transferring serum Abs from vaccinated BNP dams into healthy neonatal calves. Ab specificity was strongly associated with the presence of allogeneic MHC class I Abs in the dams. MHC class I staining was also observed on Madin–Darby bovine kidney cells, a cell line related to the one used to produce the vaccine Ag. Our report emphatically demonstrates that alloimmunization against MHC class I is associated with a substantial risk of developing cytopenia-associated syndromes in neonates when a cell line of the same species is used to produce an inactivated vaccine injected into the mother.

show abstract

Section: Discussionmentioning

confidence: 99%

Alloantibodies against MHC Class I: A Novel Mechanism of Neonatal Pancytopenia Linked to Vaccination

Foucras

Corbière

Tasca

et al. 2011

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…[26][27][28] However, severe NAITP has also recently been reported in association with anti-HPA-3a 29 and maternal HLA antibodies either alone 30 31 or in combination with HPA-1a antibodies. 32 The incidence of clinically apparent NAITP is about one in 1500 pregnancies, 25 27 although data from Ireland suggest that many neonatal cases remain undiagnosed. 28 The disease varies in severity from mild to moderate resolving in the first week of life without clinical sequelae to extensive fetal or neonatal intracranial haemorrhage (ICH) leading to death or long term neurodevelopmental sequelae.…”

Section: Common Presentations Of Thrombocytopenia In the Perinatal Pementioning

confidence: 99%

Neonatal thrombocytopenia: causes and management

Roberts

Murray²

2003

Archives of Disease in Childhood - Fetal and Neonatal Edition

172

148

View full text Add to dashboard Cite

“…Death or neurologic impairment may occur in up to 25% of the cases. Although HLA antibodies occur in up to one third of the pregnancies, the fetus is usually protected and HLA antigens have only rarely been implicated as cause of ANN or NAIT (5, 6). We report here a case of ANN and NAIT resulting from the coexistence of maternal HNA‐1a, HPA‐3b and HLA alloantibodies.…”

mentioning

confidence: 99%

Alloimmune neonatal neutropenia and thrombocytopenia associated with maternal anti HNA‐1a, HPA‐3b and HLA antibodies

Marı́n

Torı́o

Muro

et al. 2005

Pediatric Allergy Immunology

View full text Add to dashboard Cite

The incidence of alloimmune neonatal neutropenia combined with neonatal alloimmune thrombocytopenia is very low. We report a case of a neonate who suffered severe neutropenia and thombocytopenia with widespread petechial spots. The presence of alloantibodies in mother's and patient's sera was analyzed by lymphocytotoxicity test, agglutination test, granulocyte indirect immunofluorescence test, platelet immunofluorescence test (PIFT) and solid phase enzyme-linked immunosorbent assay. Human neutrophil antigens (HNA) and human platelet antigen (HPA) genotypes were tested by polymerase chain reaction analyses. The mother's and patient's sera reacted with neutrophils and lymphocytes of the father. PIFT revealed the presence of IgG anti-platelet antibodies in the patient's serum but the test was negative in the maternal serum. Analyses of HNA-1 and HPA genotypes of the family revealed maternal-neonatal HNA-1a and HPA-3b mismatch. The study of the mother's and patient's sera showed the presence of anti HNA1a, HPA-3b and HLA antibodies specific for HLA-A3 and HLA-B38 antigens. These results suggest that the transplacental passage of maternal HNA-1a, HPA-3b and HLA alloantibodies caused neutropenia and thrombocytopenia in this patient.

show abstract

Neonatal alloimmune thrombocytopenia with significant HLA antibodies

Cited by 14 publications

References 5 publications

Alloantibodies against MHC Class I: A Novel Mechanism of Neonatal Pancytopenia Linked to Vaccination

Alloantibodies against MHC Class I: A Novel Mechanism of Neonatal Pancytopenia Linked to Vaccination

Neonatal thrombocytopenia: causes and management

Alloimmune neonatal neutropenia and thrombocytopenia associated with maternal anti HNA‐1a, HPA‐3b and HLA antibodies

Contact Info

Product

Resources

About